Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 20;16(1):39-43.
doi: 10.5152/ejbh.2019.4997. eCollection 2020 Jan.

Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients

Prakash Pandit  1 , Roshankumar Patil  1 , Vijay Palwe  1 , Sucheta Gandhe  2 , Rahul Patil  2 , Rajnish Nagarkar  3
Affiliations

Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients

Prakash Pandit et al. Eur J Breast Health. .

Abstract

Objective: The aim of the study was to analyze the prevalence of molecular subtypes of all breast cancer patients treated at tertiary cancer centre in West India in 12 years.

Materials and methods: A retrospective observational study carried out in Tertiary Cancer Care Centre in Western India. Electronic medical records of all breast cancer patients were retrieved from the hospital database between March 2007 to March 2019. Patient's characteristic, histological features and molecular subtypes were collected and analyzed.

Results: A total of 2062 women fulfilled the criteria for this study and were analyzed. The median age of study population was 51 years (range 22-100 years). Among these, 1357 (65.8%) were of ≤55 years and 705 (34.2%) were over 55 years. The overall incidence of Hormonal Receptor-positive patients (either estrogen-receptor (ER) or progesterone-receptor (PR) or both) was 1162 (56.4%). The Mean tumor size was 3.8cm (range 0-18cm). The most common histology was IDC (96%). Axillary nodes were positive in 62.5%. Luminal type A was positive in 762 (37%) patients while Luminal type B was present in 157 (7.6%) patients. Basal-like subtype was observed in 537 (26%) patients while HER2 rich subtype was seen in 229 (11.1%). The incidence of Luminal A subtype increased with age. The highest observed among patients (72%) aged 70 years or more. Incidence of Basal like subtype was highest in patients less than 30 years (52%).

Conclusion: Luminal-like disease is the most common molecular subtype in India. Identification of Basal like breast cancer, a highly aggressive, biologically and clinically distinct subtype different than its non-basal variant, is important for treatment planning and target therapy.

Keywords: Retrospective observational study; breast cancer; immunohistochemistry; molecular classification; tertiary cancer centre.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Gender distribution of breast cancer at our centre
Figure 2
Figure 2
Distribution of cases as per laterality
Figure 3
Figure 3
Distribution of cases as per intent of treatment
Figure 4
Figure 4
Distribution of cases based on histological type
Figure 5
Figure 5
Distribution of cases as per molecular subtypes
Figure 6
Figure 6
Age-wise distribution of molecular subtypes in our study
See this image and copyright information in PMC

References

    1. Sung H, Rosenberg PS, Chen WQ, Hartman M, Lim WY, Chia KS, Wai-Kong Mang O, Chiang CJ, Kang D, Ngan RK, Tse LA, Anderson WF, Yang XR. Female breast cancer incidence among Asian and Western populations: more similar than expected. J Natl Cancer Inst. 2015;107:djv107. doi: 10.1093/jnci/djv107. - DOI - PMC - PubMed
    1. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11:101–115. - PMC - PubMed
    1. Rangarajan B, Shet T, Wadasadawala T, Nair NS, Sairam RM, Hingmire SS, Bajpai J. Breast cancer: An overview of published Indian data. South Asian J Cancer. 2016;5:86–92. doi: 10.4103/2278-330X.187561. - DOI - PMC - PubMed
    1. Ng CK, Schultheis AM, Bidard FC, Weigelt B, Reis-Filho JS. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. J Natl Cancer Inst. 2015;107 doi: 10.1093/jnci/djv015. pii: djv015. - DOI - PubMed
    1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. doi: 10.1038/nature11412. - DOI - PMC - PubMed

LinkOut - more resources